Jayaraman, Ramesh <br/><br/>
Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans.  [electronic resource] 

 -  Drug metabolism letters  2015 
 - 28-47 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1874-0758 
<br/><br/><label>Standard No.: </label>10.2174/1872312809666150119105250  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Animals<br/>Biological Availability<br/>Biotransformation<br/>Bridged-Ring Compounds--administration & dosage<br/>Cells, Cultured<br/>Cytochrome P-450 CYP3A--metabolism<br/>Dealkylation<br/>Dogs<br/>Feces--chemistry<br/>Hepatobiliary Elimination<br/>Hepatocytes--metabolism<br/>Humans<br/>Janus Kinase 2--antagonists & inhibitors<br/>Liver--metabolism<br/>Male<br/>Metabolic Clearance Rate<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Microsomes, Liver--metabolism<br/>Models, Biological<br/>Oxidation-Reduction<br/>Protein Binding<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Rats<br/>Rats, Wistar<br/>Species Specificity<br/>Tissue Distribution